- About Us
- Reproductive Health & Pregnancy Therapeutics
- Our Pipeline
- News & Events
Uterine fibroids are common non-cancerous tumors that grow within the muscular wall of the uterus. They can vary in size and number and when symptomatic, are most often accompanied by heavy menstrual bleeding (HMB), anemia, abdominal pressure and pain, bloating, increased urinary frequency and reproductive dysfunction. Uterine fibroids are associated with an increased risk of pregnancy complications such as infertility, miscarriage, placental abruption, and early onset of labor.
For the millions of women with symptomatic uterine fibroids seeking treatment options, selection is driven by symptom severity, the woman’s age, and her desire to have children now or in the future. While medical, surgical and minimally invasive treatments are available, the standard of care for symptomatic uterine fibroids is a hysterectomy or, in women who wish to preserve their fertility, surgical removal of the fibroid(s).
ObsEva is currently advancing OBE2109, a novel, oral gonadotropin-releasing hormone (GnRH) receptor antagonist that potentially provides effective management of UF-associated HMB while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments.
For a list of all ObsEva clinical trials in the area of uterine fibroids, click here.